Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 20
Healthy Volunteers: f
View:

• VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.

• VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.

Locations
Other Locations
Taiwan
National Taiwan University Hospital
RECRUITING
Taipei
Time Frame
Start Date: 2025-06-02
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 1000
Treatments
Other: AI Intervention
Patients will undergo fundus photography screening using artificial intelligence-assisted diagnostic software (VeriSee). Ophthalmologists will independently interpret the same images, and the results will be compared with those generated by the AI.
Sponsors
Collaborators: Fu Jen Catholic University Hospital, Min-Sheng General Hospital, Ministry of Health and Welfare, Taiwan
Leads: National Taiwan University Hospital

This content was sourced from clinicaltrials.gov